| Typicality: | 0.408 |
| Saliency: | 0.371 |
| for the first time | 39 | manner |
| in phase | 13 | temporal |
| to prevent the hormone | 3 | purpose |
| researcher → test → experimental drug | 26 |
| researcher → use → experimental drug | 7 |
| researcher → test → experimental drugs | 3 |
| negative | neutral | positive |
| 0.078 | 0.835 | 0.087 |
| Raw frequency | 36 |
| Normalized frequency | 0.371 |
| Modifier score | 0.500 |
| Perplexity | 129.327 |